CONTEXT: Elevated blood levels of lidocaine and ropivacaine have been described after transversus abdominis plane (TAP) block. OBJECTIVE: To investigate the pharmacokinetic profile of ropivacaine after bilateral TAP blocks. DESIGN: Prospective observational pharmacokinetic study. SETTING: University teaching hospital in Copenhagen, Denmark. PATIENTS: Twenty-one adult patients presenting for abdominopelvic surgery with bilateral TAP blocks were enrolled. PROCEDURES: Ultrasound-guided TAP blocks with bilateral injections of 20 ml ropivacaine 0.5% w/v (total dose 200 mg). Blood was sampled at 0, 10, 30 and 60 min after TAP blocks. MEASURES: Total and free peak blood concentrations (Cmax) of ropivacaine. RESULTS: Data were analysed from N = 18 patients. The median dose of ropivacaine was 2.7 mg kg(-1) (range: 1.9-4.2 mg kg(-1)). Median total ropivacaine concentrations were 1.0, 1.6 and 1.7 μg ml(-1) at 10, 30 and 60 min, respectively. Six patients (33%) had Cmax values above 2.2 μg ml(-1) and the highest concentration measured was 5.1 μg ml(-1). One patient had a 33% drop in mean arterial blood pressure. CONCLUSION: TAP blocks with bilateral injections of 20 ml ropivacaine 0.5% w/v gave rise to potentially toxic peak blood concentrations of total ropivacaine in one-third of the patients.
CONTEXT: Elevated blood levels of lidocaine and ropivacaine have been described after transversus abdominis plane (TAP) block. OBJECTIVE: To investigate the pharmacokinetic profile of ropivacaine after bilateral TAP blocks. DESIGN: Prospective observational pharmacokinetic study. SETTING: University teaching hospital in Copenhagen, Denmark. PATIENTS: Twenty-one adult patients presenting for abdominopelvic surgery with bilateral TAP blocks were enrolled. PROCEDURES: Ultrasound-guided TAP blocks with bilateral injections of 20 ml ropivacaine 0.5% w/v (total dose 200 mg). Blood was sampled at 0, 10, 30 and 60 min after TAP blocks. MEASURES: Total and free peak blood concentrations (Cmax) of ropivacaine. RESULTS: Data were analysed from N = 18 patients. The median dose of ropivacaine was 2.7 mg kg(-1) (range: 1.9-4.2 mg kg(-1)). Median total ropivacaine concentrations were 1.0, 1.6 and 1.7 μg ml(-1) at 10, 30 and 60 min, respectively. Six patients (33%) had Cmax values above 2.2 μg ml(-1) and the highest concentration measured was 5.1 μg ml(-1). One patient had a 33% drop in mean arterial blood pressure. CONCLUSION: TAP blocks with bilateral injections of 20 ml ropivacaine 0.5% w/v gave rise to potentially toxic peak blood concentrations of total ropivacaine in one-third of the patients.
Authors: Sean H Flack; Lizabeth D Martin; Benjamin J Walker; Adrian T Bosenberg; Laurilyn D Helmers; Adam B Goldin; Charles M Haberkern Journal: Paediatr Anaesth Date: 2014-05-22 Impact factor: 2.556
Authors: Eric Albrecht; Kyle R Kirkham; Ryan V W Endersby; Vincent W S Chan; Timothy Jackson; Allan Okrainec; Todd Penner; Rongyu Jin; Richard Brull Journal: Obes Surg Date: 2013-08 Impact factor: 4.129
Authors: P Miranda; M A Corvetto; Fernando R Altermatt; A Araneda; G C Echevarría; L I Cortínez Journal: Eur J Clin Pharmacol Date: 2016-07-14 Impact factor: 2.953